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and disease-free, 7 are alive with disease, 12 patients died of 
disease and 8 of other causes. The 3-year probability of LRFS, 
DMFS and CSS was 87.1% (95% CI: 0.69-0.95), 80.1% (95% CI: 
0.65-0.90) and 77.5% (95% CI: 0.61-0.88) respectively. Median 
survival was not reached for LRFS or MFS; it was 73 months 
(95%IC:46-100) for CSS. In univariate analysis surgery 
influenced tumour-related deaths (67 months, 95%CI: 59.2-
74.9 vs 20.2 months, 95%CI: 4.5-35.9; p=0.001) and mean 
distant metastasis survival (65 months, 95%CI: 57.7-73 vs 47 
months, 95%CI: 20.2-73.8; p=0.046); only stage pIIIC was 
significantly associated with probability of a shorter survival 
time due to distant metastases (p=0.002); In multivariate 
Cox-regression analysis, pathological stage, adjusted for age, 
grading and TRG, was significantly associated with MFS (HR: 
5.411; 95%CI: 1.395-21; p=0.015) and tumour-related death 
(HR: 2.629; 95%CI: 1.245-5.554; p=0.011). Treatment was 
well tolerated with no acute or late grade III-IV toxicity.  
Conclusions: short-course RT followed by delayed surgery is 
feasible, well-tolerated and provides a high pathological 
response rate.  
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Purpose/Objective: To determine the safety?efficacy and 
prognostic factors of intensity modulated radiotherapy 
(IMRT)for a cohort of patients with primary large 
hepatocellular carcinoma (LHCC) unresectable and unsuitable 
of other standard therapies. 
Materials and Methods: This is a single institution 
retrospective analysis of 29 patients with unresectable large 
hepatocellular carcinoma (≥5 cm) was treated with IMRT 
from April 2008 to August 2011.Daily dose from 2 to 3Gy was 
delivered at five fractions per week to deliver a total dose of 
50 to 70Gy, at least 95% of the planning target volume (PTV) 
to receive 100% of the prescribed dose. 20 patients were 
treated under a multi-modality treatment algorithm and had 
undergone transarterial chemoembolization (TACE) or 
radiofrequency ablation (RFA) prior to IMRT. After treatment, 
every 2-3 months later,such as the abdomen magnetic 
resonance imaging or contrast-enhanced CT to evaluate the 
efficacy and prognosis. Overall survival (OS) and progression 
free survival (PFS) were determined by Kaplan-Meier analysis. 
Tumor response and toxicities were also assessed. univariate 
analysis using the Log-rank method, Cox regression model for 
multivariate analysis, p<0.05 was considered statistically 
significant. 
Results: After a median follow-up of 12.5 month (range, 3-40 
months). 
One patient with bilirubin increased couldn't be completed 
radiotherapy. 28 patients who received IMRT CR 3.57%, PR 
32.14%, SD 53.57%, PD 10.72%, total effective rate was 
35.71%, the local control rate was 89.28%.The overall median 
progression-free survival (PFS) 6.43 months and median 
survival (OS) 11.43 months .The 1,2-year survival rates were 
46.79%, 25.23%,respectively. Univariate analysis showed that 
the tumor response rate (p=0.01) was an independent 
prognostic factor for PFS, COX multivariate analysis showed 
that the independent prognostic factor for PFS were tumor 
response rate (p=0.00) and RT dose (p=0.03), OS independent 
prognostic factors were tumor response rate (p=0.00), tumor 
size (p=0.01), tumor volume (p=0.03). The most common 
acute toxicities included gastrointestinal discomfort, 
radiation-induced liver damage and myelosuppression. There 
was no radiation-induced liver disease or treatment-related 
grade 4/5 toxicity. 
Conclusions: This study suggests IMRT is a practical 
treatment option for LHCC patients which surgical and other 
local therapies are unsuitable or ineffective. 
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Purpose/Objective: Definitive chemo-radiotherapy is a 
standard of care for oesophageal carcinoma patients not fit 
for surgery. However, there are a significant number of 
patients with loco-regional disease, who are unfit for 
chemotherapy due to co-morbities, inadequate renal function 
or poor performance status. In this group, radiotherapy alone 
can be considered as a definitive treatment. Different 
techniques and dose fractionations have been employed with 
radical or palliative intent, with no clear consensus. This 
study analysed the relapse patterns and subsequent outcome 
for patients treated at a large single UK centre with 
radiotherapy alone given with the radical intent.  
Materials and Methods: A retrospective analysis was 
performed to assess relapse patterns and subsequent 
outcome for 142 sequential patients who received 55Gy in 20 
fractions of radiotherapy for oesophageal cancer at the 
Christie hospital, Manchester, UK, from June 2009 to 
September 2013. Time to relapse was calculated from start 
date of radiotherapy. Recurrence at primary site or regional 
lymph nodes was considered as a local recurrence. Kaplan-
Meier method was used for analysis of survival data. 
Results: Relapses were identified in 39.4% (n=56) of patients. 
Among these 56 patients, the presenting site of disease at 
diagnosis was upper third for 3 patients, middle third for 13, 
lower third for 26 and 14 patients had gastro-oesophageal 
junction carcinoma. The presenting histology was 
adenocarcinoma for 57.1 % (n=32) and squamous cell 
carcinoma for 42.9% (n=24) of patients. 10 out of 56 patients 
had stage I disease, 19 had stage II disease and 27 had stage 
III disease at initial presentation. At relapse, 50% (n=28) 
experienced a local recurrence only, 21.4% (n=12) had local 
recurrence and distant metastasis, and 28.6% (n=16) had 
distant metastasis alone. Among those recurring locally, 87.5 
% had recurrence within radiotherapy fields. Median time to 
relapse was 247.5 days (range 43 days- 1378 days) and 
median survival noted following relapse was 178 days (range 
4 days- 711 days). 
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Conclusions: A high proportion of patients experienced a 
local relapse alone following treatment suggesting that 
radiotherapy alone without chemo-sensitisation does not 
achieve high rates of local control. The use of alternate 
approaches such as brachytherapy to provide a local boost 
may have merit and warrants further investigation. Despite 
this, there are some patients who achieve respectable 
relapse free survival and overall survival, but others where a 
palliative approach might be more appropriate. Further work 
needs to be done to understand the factors influencing 
patient outcomes following definitive radiotherapy. Further 
refinement in patient selection will follow with better 
understanding of radio-genomic profiling. 
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Purpose/Objective: To evaluate toxicity and outcomes of 
patients with anal canal cancer treated with 
hypofractionated radiotherapy schedule and a Simultaneous 
Integrated Boost with Helical Tomotherapy. 
Materials and Methods: From March 2009 to March 2014 41 
patients were treated with simultaneous integrated boost- 
intensity modulated radiotherapy and concurrent 
chemotherapy for anal canal squamous carcinoma. Two 
clinical target volumes were delineated, radiotherapy dose 
was adapted to disease stage: 50.6 Gy and 41.4 Gy in 23 
fractions in T1N0, 52.8 Gy and 43.2 Gy in 24 fractions in T2N0 
and 55 and 45 Gy in 25 fractions in all patients with N+ 
and/or ≥T3, prescribed to Planning Target Volume 1 and 
Planning Target Volume 2 respectively. The most common 
chemotherapy regimen was 5-fluorouracil and mitomycin 
based. 
Results: The median age was 63 years (range 32-84). 5, 10, 
11 and 14 patients were respectively in stage I, II, IIIA and 
IIIB. A complete response was achieved in 34/38 (89.4%) 
patients evaluable for outcomes, one partial response in 1 
patient, inoperable persistence of disease was observed in 1 
patient and progressive disease in 2 patients (local and 
metastatic respectively). Acute grade 3 skin and grade 3 
gastrointestinal toxicity was reported in 5% and 7.3% of 
patients, respectively; treatment breaks due to toxicity were 
required in 7.3% of patients. With a median follow up of 20 
months, the 2-year overall survival and disease free survival 
were 90.4% and 92.3%. 
Conclusions: In our experience, intensity modulated 
radiotherapy with simultaneous integrated boost is feasible 
and allows the obtainment of excellent results data in terms 
of overall survival, local control and toxicity without several 
breaks due to acute toxicity. 
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Purpose/Objective: The purpose of this study was to 
retrospectively assess the clinical outcome in anal cancer 
patients treated with curative intent chemo-radiotherapy in 
terms of local control (LC), distant metastases-free survival 
(DMFS) and overall survival (OS). 
Materials and Methods: From January 2002 to December 
2012, 125 patients were treated for anal carcinoma in our 
Department of Radiotherapy in Policlinico S. Orsola-Malpighi, 
Bologna. The treatment consisted of 3DCRT on the pelvis 
(median dose: 45 Gy /1.8 Gy) with concurrent chemotherapy 
(5-fluorouracil and Mitomycin-C). After a clinical response 
evaluation patients received a boost 2-3 weeks after the end 
of the 3D-CRT by either pulsed dose rate brachytherapy (80% 
of the patients, mean dose: 18.5 Gy) or without any 
interruption by external beam radiotherapy (20%, mean dose 
16.4 Gy) in patients with controindications to brachytherapy. 
Exclusion criteria for brachytherapy were: initial diffusion of 
cancer > 2/3 of circumpherence of anal canal, initial 
extended diffusion at the perianal skin, presence of a 
residual >5 cm in longitudinal or >1,5 cm in deepth after 3D-
CRT (first course) and the clinical controindication for 
anesthesia. LC, DMFS and OS were analyzed using Kaplan-
Meier method. A comparison of the survival curves was 
performed using long rank test (univariate analysis). 
Results: Males were 31 (25%), females 94 (75%). Median age 
was 61 years (range 37-94 years), elderly patients (over 65 
years-old) were 53 (42%). Tumor stage was T1 in 18 patients 
(14%), T2 in 45 patients (36%), T3 in 41 patients (33%), T4 in 
21 patients (17%). Nodal stage was N0 in 71 patients (57%), 
N1 in 29 (23%), N2 in 13 (10%). The histology was squamous-
cell carcinoma (78%) and non squamous-cell carcinoma (22%). 
HIV+ e HPV+ patients were 7 (6%) and 2 (2%), respectively. 
Median follow-up was 43 months (range: -132 months). The 5-
year LC rate was 83%. No significant association between 5-
year LC and clinicopathologic factors (age, T stage, N stage, 
histology, and HIV status) was recorded (p: NS). The 5-year 
DMFS was 93%. N stage was significantly correlated with 5-
year metastasis free survival (p<0.05). The 5-year OS was 
73.5%. T status was significantly associated with 5 year OS 
(p= 0.035). 
 
 
Conclusions: Our results confirmed that radiochemotherapy 
